Evaluation of preference for a novel durable insulin pen with memory function among patients with diabetes and health care professionals

Patient Preference and Adherence

Volumn 7, Issue , 2013, Pages 285-292

  Klausmann, Gerhard ^a   Hramiak, Irene ^b   Qvist, Marianne ^c   Mikkelsen, Kristian Handberg ^c   Guo, Xiaohui ^d  

^a St Joseph's Healthcare ^*

^b Division of Endocrinology and Metabolism   (Canada)

^c NOVO NORDISK A S   (Denmark)

^d PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Confidence; Diabetes; Durable insulin pen; Memory function; Patient preference; Usability

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS; DIABETIC PATIENT; DRUG DELIVERY DEVICE; EQUIPMENT DESIGN; FEMALE; HEALTH CARE PERSONNEL; HEALTH PERSONNEL ATTITUDE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PEN; INSULIN PEN WITH MEMORY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEEDLE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT PREFERENCE; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

EID: 84876122549     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S41929     Document Type: Article

References (29)

1. Zhang P, Zhang X, Brown J, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(3): 293-301.
2. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94(3):311-321.
3. Morrow AS, Haidet P, Skinner J, Naik AD. Integrating diabetes self-management with the health goals of older adults: a qualitative exploration. Patient Educ Couns. 2008;72(3):418-423.
4. Lernmark A. Type 1 diabetes. Clin Chem. 1999;45(8 Pt 2):1331-1338.
5. [No authors listed]. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131): 837-853.
6. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002;25(2):330-336.
7. Charbonnel B, Penfornis A, Varroud-Vial M, Kusnik-Joinville O, Detournay B. Insulin therapy for diabetes mellitus: treatment regimens and associated costs. Diabetes Metab. 2012;38(2):156-163.
8. Brunton S. Insulin delivery systems: reducing barriers to insulin therapy and advancing diabetes mellitus treatment. Am J Med. 2008; 121(Suppl 6):S35-S41.
9. Donnelly LA, Morris AD, Evans JM. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. QJM. 2007;100(6):345-350.
10. Charbonnel B, Penfornis A, Varroud-Vial M, Kusnik-Joinville O, Detournay B. Insulin therapy for diabetes mellitus: treatment regimens and associated costs. Diabetes Metab. 2012;38(2):156-163.
11. Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care. 2010;33(2):240-245.
12. Randlov J, Poulsen JU. How much do forgotten insulin injections matter to hemoglobin A1c in people with diabetes? A simulation study. J Diabetes Sci Technol. 2008;2(2):229-235.
13. Ross SA, Tildesley HD, Ashkenas J. Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes. Curr Med Res Opin. 2011;27 Suppl 3:13-20.
14. Korytkowski M, Bell D, Jacobsen C, Suwannasari R. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003;25(11):2836-2848.
15. Lombardo F, Salzano G, Messina MF, De Luca F. Compliance and administration methods in management of type 1 diabetes. Acta Biomed. 2005;76 Suppl 3:66-69.
16. Olsen BS, Lilleore SK, Korsholm CN, Kracht T. Novopen Echo for the delivery of insulin: a comparison of usability, functionality and preference among pediatric subjects, their parents and health care professionals. J Diabetes Sci Technol. 2010;4(6):1468-1475.
17. Sommavilla B, Jorgensen C, Jensen KH. Safety, simplicity and convenience of a modified prefilled insulin pen. Expert Opin Pharmacother. 2008;9(13):2223-2232.
18. Summers KH, Szeinbach SL, Lenox SM. Preference for insulin delivery systems among current insulin users and nonusers. Clin Ther. 2004;26(9):1498-1505.
19. Asche CV, Shane-McWhorter L, Raparla S. Health economics and compliance of vials/syringes versus pen devices: a review of the evidence. Diabetes Technol Ther. 2010;12 Suppl 1:S101-S108.
20. Baser O, Bouchard J, DeLuzio T, Henk H, Aagren M. Assessment of adherence and healthcare costs of insulin device (FlexPen) versus conventional vial/syringe. Adv Ther. 2010;27(2):94-104.
21. Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of thirdparty managed care claims data. Clin Ther. 2006;28(10):17121725.
22. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin. adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012;29(5):682-689.
23. Guo X, Sommavilla B, Vanterpool G, Qvist M, Bethien M, Lilleore SK. Evaluation of a new durable insulin pen with memory function among people with diabetes and healthcare professionals. Expert Opin Drug Deliv. 2012;9(4):355-356.
24. World Medical Association. Declaration of Helsinki - ethical principles for medical research involving human subjects. Available from: http://www.riip-influenza.org/wp-content/uploads/2011/08/Helsinki-2008--EN.pdf. Accessed November 8, 2011.
25. Buus P, Lilleore SK, Larsen K. Compatibility testing of two types of pen needles with a range of injection pens for diabetes medication. Curr Med Res Opin. 2011;27(3):589-592.
26. Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361(18): 1736-1747.
27. Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007; 357(17):1716-1730.
28. [No authors listed]. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005;28(5):1245-1249.
29. Fidler C, Elmelund Christensen T, Gillard S. Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs. J Med Econ. 2011;14(5):646-655.